---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104570"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:00:43.468604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q2 2025 R&D expenses $37.6M, cash $194.7M; myositis registrational cohort on track for 2H25

## Summary
- R&D expenses $37.6M (vs $23.4M in Q2 2024); G&A $8.3M (vs $6.9M).
- Cash, cash equivalents & short-term investments $194.7M as of June 30, 2025; runway into 2H26.
- Closed $100M public offering (net ~$94M) in June 2025 to support rese-cel development and commercial readiness.
- Myositis registrational cohort enrollment on track for 2H25; first BLA submission for rese-cel anticipated in 2027.
- FDA meetings planned for lupus (3Q25), scleroderma (4Q25), and myasthenia gravis (1H26) registrational designs.

## SEC filing metadata
- accession: 0000950170-25-104570
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000095017025104570/0000950170-25-104570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000095017025104570/caba-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104570
- JSON: https://secwatch.observer/filing/0000950170-25-104570.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.